CALQUENCE (acalabrutinib), AstraZeneca
Indications: A kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Dosage: 100 mg orally approximately every 12 hours, with or without food. Advise patients not to break, open, or chew capsules. Manage toxicities using treatment interruption, dose reduction, or discontinuation.